Prognostic role of caveolin in breast cancer: A meta-analysis Ma X et al., Prognostic role of caveolin in breast cancer: A meta-analysis The Breast (2013)

Slides:



Advertisements
Similar presentations
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Advertisements

Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Can We Define Tumors That Will Respond to PARP Inhibitors? A Phase II Correlative Study of Olaparib in Advanced Serous Ovarian Cancer and Triple-Negative.
Model and Variable Selections for Personalized Medicine Lu Tian (Northwestern University) Hajime Uno (Kitasato University) Tianxi Cai, Els Goetghebeur,
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
PROGNOSTIC SIGNIFICANCE OF PRIMARY TUMORAL FDG UPTAKE MEASURED BY PET: Systematic Review and Meta-analysis Ben A. Dwamena, MD.
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
CO-I KNTM/K i CzS M. Sklodowska-Curie Memorial Cancer Center-Institute of Oncology Medical University of Warsaw; Warsaw, POLAND Medical University of Gdansk;
Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
PrognoScan A new database for meta-analysis of the prognostic value of genes 1 Hideaki Mizuno, Kunio Kitada, Kenta Nakai, Akinori Sarai BMC Med Genomics.
10 Minutes Talk 吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.
Changes in Tumor Growth and Metastatic Capacities of J82 Human Bladder Cancer Cells Suppressed by Down-regulation of Calreticulin Expression Speaker: Yi-Chien.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
A Systematic Review On The Hazards Of Aspirin Discontinuation Among Patients With Or At Risk For Coronary Artery Disease Giuseppe Biondi Zoccai Hemodynamics.
Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1,
ARTERIAL THROMBOEMBOLIC EVENTS IN A POOLED ANALYSIS OF 5 RANDOMIZED, CONTROLLED TRIALS OF BEVACIZUMAB WITH CHEMOTHERAPY JR Skillings Genentech, Inc, South.
A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft-tissue sarcoma Nabeel Pervaiz Nigel.
Huidi Liu, M.D. & Ph.D Genomics Research Centre Harbin Medical University, China Reduced expression of SOX7 in ovarian cancer: a novel.
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
*University Hospital Gasthuisberg, Leuven, Belgium
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.
CHFR METHYLATION AS AN EPIGENETIC MARKER FOR RECURRENCE OF COLON CANCER M. D. Anderson Cancer Center, Houston, Texas Motofumi Tanaka, Salil Sethi, Donghui.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.
Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.
Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer In association.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
Meta-analysis of observational studies Nicole Vogelzangs Department of Psychiatry & EMGO + institute.
COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.
The role of regulatory B cells on hepatocellular carcinoma progression Conclusion Results Fig2. (A and B) In vivo, Bregs in SCID mice increased the size.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
P53 PROTEIN EXPRESSION AND ITS CORRELATION WITH CELL PROLIFERATION IN COLORECTAL CANCER Dear proffesors, dear collegues please let me introduce you.
Prognostic significance of tumor subtypes in male breast cancer:
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
Immunoscore Prognostic in Colon Cancer
Farletuzumab in platinum sensitive ovarian cancer with low CA125
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
Fig 1A. Patient enrollment flow chart
Progression markers of human epithelial-type ovarian tumors
Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors of Survival J Tabernero,
Yu-fang huang, yi-hui wu, cheng-yang chou*
Canine invasive mammary carcinoma as a spontaneous model
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
Volume 15, Pages (February 2017)
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
But how to treat those with positive SLNB? Results and Discussion
Supporting Information for Meta-analysis
Taipei Veterans General Hospital,
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung
2018/03/18 外科年會 Oral Presentation
Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT  Zhen-Yu He, San-Gang Wu, Fang Peng,
Published online September 20, 2017 by JAMA Surgery
Mezale D*1, Strumfa I1, Balodis D1, Vanags A2, Rumba R2
Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
High CDK6 expression predicts poor prognosis in EOC patients
GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR
The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma(
Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.
Presentation transcript:

Prognostic role of caveolin in breast cancer: A meta-analysis Ma X et al., Prognostic role of caveolin in breast cancer: A meta-analysis The Breast (2013) Jing Zhang West China Hospital, China

 Background  Materials & methods  Results & Discussion  Conclusion Outline

 Background  Materials & methods  Results & Discussion  Conclusion Outline

1. Breast cancer  Most frequently diagnosed cancer and the leading cause of cancer death in females worldwide.  Accounting for 23% (1.38 million) of the total new cancer cases & 14% (458,400) of the total cancer deaths.  Recurrence rate is high, eg: Triple-negative breast cancer (TNBC): 34% Jemal A. Global cancer statistics. CA Cancer J Clin(2011) Background

1. Breast cancer  Biomarkers: p53 mutation, cyclin E, BRCA1 methylation...  A heatedly studied biomarker recently: caveolin (Cav) Background

2. Caveolin  Integral membrane protein in mesenchymal cells, such as adipocytes, endothelial cells, and fibroblasts. Background Membrane organizing centers

2. Caveolin family: Background Cav-1 Cav-2 Cav-3

2. Caveolin  Nam KH. Caveolin 1 expression correlates with poor prognosis and focal adhesion kinase expression in gastric cancer. Pathobiology (2013)  Tang Y.Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer. Med Oncol (2012)  Steffens S. Caveolin 1 protein expression in renal cell carcinoma predicts survival. BMC Urol (2011)  Others : atherosclerosis, restrictive lung disease, pulmonary fibrosis, cardiomyopathy, muscular dystrophy, and bladder dysfunction. Background

3. Caveolin & breast cancer  Recently, both the epithelial and stromal caveolin have been detected in breast cancer patients to determine the prognosis.  In vitro studies have shown that both stromal and epithelial Cav- 1 play a protective role against mammary hyperplasia and tumor genesis in breast cancer.  Williams TM. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells.Am J Pathol(2006) Background

3. Caveolin & breast cancer  However, the prognostic role of stromal and epithelial Cav-1 varied in many clinical studies.  Liedtke C. Caveolin-1 expression in benign and malignant lesions of the breast.World J Surg Oncol(2007)  Qian N.Prognostic significance of tumor/stromal caveolin-1 expression in breast cancerpatients.Cancer Sci(2011) Background

4. Aim of this study  To clarify whether caveolin could be a prognostic factor for patients with breast cancer. Background

 Background  Materials & methods  Results & Discussion  Conclusion Outline

1. Search strategy  Database: Pubmed and EMBASE  Search on April 26, 2012  Keywords: “caveolin”, “breast cancer”, “prognosis” Materials & methods

2. Study inclusion criteria  (i) patients with breast cancer  (ii) the expression of caveolin in tumor epithelial or stromal cells was measured  (iii) the association between caveolin expression and survival outcome (OS/CSS/PFS/DFS) was analyzed Materials & methods

3. Study exclusion criteria  (i) review, letter or experiment on animal models  (ii) not patients with breast cancer  (iii) not about caveolin expression  (iv) lacked key information for hazard ratio (HR) estimation analysis Materials & methods

4. Data extraction  Article review & Data extraction: two investigators.  (i) Baseline characteristics  (ii) Survival outcomes (the Kaplane-Meier survival curves and p values OR Hazard ratios (HR) and 95% confidence interval (CI)) Materials & methods

5. Statistical analysis  Aggregation of the survival results: logHR and Standard errors (SE)  Subgroup analysis  Forrest plots  An observed HR>1 indicated a worse outcome  Software: RevMan 5.1 & STATA 11.0 Materials & methods

 Background  Materials & methods  Results & Discussion  Conclusion Outline

Results & Discussion 1. Selection of studies

Results & Discussion 2. Baseline characteristics-1

Results & Discussion 2. Baseline characteristics-2

Results & Discussion  3. Caveolin & Survival outcome 3.1 stromal Cav-1 (A: OS B: DFS/PFS)

Results & Discussion  3. Caveolin & Survival outcome 3.2 tumor epithelial Cav-1 (C: OS D: DFS/PFS)

Results & Discussion 3. Caveolin & Survival outcome 3.3 tumor epithelial Cav-2 (E: CSS)

Results & Discussion 3. Caveolin & Survival outcome – summary Negative expression of stromal Cav-1 was associated with poor prognosis of breast cancer, while the detection of Cav-1 and Cav-2 in tumor epithelial cells was not.

Results & Discussion 4. Assessment of publication bias Begg’s funnel plot and test Typep value stromal Cav-1--OS0.042 stromal Cav-1--DFS/PFS0.497 epithelial Cav-1--OS0.497 epithelial Cav-1--DFS/PFS0.652 epithelial Cav-2--CSS0.602

5. Potential mechanism  Most researchers view:  Epithelial–mesenchymal transition (EMT)  A process by which epithelial cells lose their cell polarity and cell-cell adhesion, and gain migratory and invasive properties to become mesenchymal stem cells. Results & Discussion

5. Potential mechanism  Epithelial–mesenchymal transition (EMT) Results & Discussion From: wikipedia

5. Potential mechanism  Epithelial–mesenchymal transition (EMT)  EMT is essential for numerous developmental processes including mesoderm formation and neural tube formation.  EMT has also been shown to occur in wound healing, in organ fibrosis and in the initiation of metastasis for cancer progression. Results & Discussion From: wikipedia

5. Potential mechanism  Negative expression of Cav-1  Epithelial–mesenchymal transition (EMT)  Initiation and completion of the invasion-metastasis cascade  Poor prognosis of breast cancer Results & Discussion

6. Application:  Immunohistochemistry, Immunofluorescence, Western blot Results & Discussion

7. Limitations  Multivariate survival analysis VS univariate  DFS and PFS together as DFS/PFS group  Publication bias  Definition of low & high expression of Cav Results & Discussion

8. Future research:  1. The underlying mechanism.  2. Quantification and cut-off value in the detection of caveolin. Results & Discussion

 Background  Materials & methods  Results & Discussion  Conclusion Outline

 Our results indicated that negative expression of stromal Cav-1 was associated with poor prognosis of breast cancer, while the detection of Cav-1 and Cav-2 in tumor epithelial cells was not.  However, these results should be confirmed by adequately multi-center designed prospective studies in the future. Conclusion

Thanks for your attention! Jing Zhang West China Hospital, China